Work

Impact of Prior Lines of Systemic Therapy (PST) on the Efficacy Of Cemiplimab, a Human Monoclonal Anti–PD-1, in Patients (PTS) with Advanced Cutaneous Squamous Cell Carcinoma (CSCC)

Year: 2019

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdz451.006

Authors: D. Rischin, N.I. Khushalani, C.D. Schmults, A. Guminski, A.L.S. Chang, K.D. Lewis, A.M. Lim, L. Hernandez-Aya, B.G.M. Hughes, D. Schadendorf, A. Hauschild, E. Stankevich, J. Booth, S. Li, Z. Chen, J. Desai, I. Lowy, M.G. Fury, M.R. Migden

Institutions: Peter MacCallum Cancer Centre, Peter MacCallum Cancer Foundation, Moffitt Cancer Center, Brigham and Women's Hospital, Harvard University, Royal North Shore Hospital, Stanford Medicine, Stanford University, University of Colorado Cancer Center, Sir Charles Gairdner Hospital, Washington University in St. Louis, The University of Queensland, Royal Brisbane and Women's Hospital, Essen University Hospital, Deutsches Konsortium für Translationale Krebsforschung, University Hospital Schleswig-Holstein, Regeneron (United States), The University of Texas MD Anderson Cancer Center

Language: English

Topic: Nonmelanoma Skin Cancer Studies

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2995104549

FWCI: 0.165

Cites:

Cited by: 2

Related to: 10